Drug Profile
Research programme: phosphatidylinositol 3-kinase gamma inhibitors - Merck Serono
Alternative Names: AS-606839Latest Information Update: 07 Mar 2011
Price :
$50
*
At a glance
- Originator Merck Serono
- Class Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 07 Mar 2011 Discontinued - Preclinical for Multiple sclerosis in Switzerland (PO)
- 07 Mar 2011 Discontinued - Preclinical for Rheumatoid arthritis in Switzerland (PO)
- 04 Sep 2008 Preclinical trials in Multiple sclerosis in Switzerland (PO)